News
VIVS
1.190
-0.83%
-0.010
Weekly Report: what happened at VIVS last week (0601-0605)?
Weekly Report · 1d ago
Weekly Report: what happened at VIVS last week (0525-0529)?
Weekly Report · 06/01 09:15
Weekly Report: what happened at VIVS last week (0518-0522)?
Weekly Report · 05/25 09:16
Weekly Report: what happened at VIVS last week (0511-0515)?
Weekly Report · 05/18 09:16
Weekly Report: what happened at VIVS last week (0504-0508)?
Weekly Report · 05/11 09:15
Weekly Report: what happened at VIVS last week (0427-0501)?
Weekly Report · 05/04 09:15
VivoSim AI model predicts drug diarrhea risk with 96% accuracy using human intestinal tissues
PUBT · 04/28 12:19
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
Barchart · 04/28 07:05
Weekly Report: what happened at VIVS last week (0420-0424)?
Weekly Report · 04/27 09:15
Weekly Report: what happened at VIVS last week (0413-0417)?
Weekly Report · 04/20 09:14
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 04/17 21:05
Weekly Report: what happened at VIVS last week (0406-0410)?
Weekly Report · 04/13 09:15
Weekly Report: what happened at VIVS last week (0330-0403)?
Weekly Report · 04/06 09:15
VivoSim Labs Prices Best-Efforts Public Offering
TipRanks · 04/03 20:38
VivoSim prices up to $4 million best-efforts public offering at $1.14 a share
Reuters · 04/03 20:06
VivoSim Labs Fall 34% After Pricing Up To $4 Million Public Offering
NASDAQ · 04/01 12:38
VivoSim Labs Announces The Pricing Of Up To A $4M Best-Efforts Public Offering, With $3M Funded At An Initial Closing Of The Offering
Benzinga · 04/01 12:08
VivoSim Labs prices up to $4 million best-efforts public offering
Reuters · 04/01 12:06
VivoSim launches $4M offering with warrants and two-tranche structure
Seeking Alpha · 03/30 15:01
Weekly Report: what happened at VIVS last week (0323-0327)?
Weekly Report · 03/30 09:15
More
Webull provides a variety of real-time VIVS stock news. You can receive the latest news about VivoSim Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About VIVS
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company, which is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models.